Fulgent Genetics faces legal probe after missing revenue targets
Fulgent Genetics, Inc. is facing scrutiny after its latest financial results raised concerns. The company reported a drop in revenue for the fourth quarter, missing its own updated forecasts. Now, law firm Lowey Dannenberg P.C. is examining whether securities laws were broken in the process. The company’s full-year revenue for 2025 reached approximately $322.7 million. However, this figure came in just below the guidance Fulgent Genetics had previously revised. The shortfall followed a noticeable decline in earnings during the final quarter of the year.
The sequential drop in fourth-quarter revenue has drawn attention from investors and regulators alike. Legal firm Lowey Dannenberg P.C. has since launched an investigation into potential violations of securities laws by the company.
The probe will focus on whether Fulgent Genetics complied with financial disclosure rules. Shareholders and market watchers are now awaiting further details on the investigation’s findings. The outcome could have implications for the company’s future reporting practices.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Over 1.7M in Baden-Württemberg at Poverty Risk, Emmendingen's Housing Crisis Urgent
- Life Expectancy Soars, But Youth Suicide and Substance Abuse Pose Concern
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
